Taio Naniwa

Overview

Explore the profile of Taio Naniwa including associated specialties, affiliations and a list of published articles.

Snapshot

Articles 60

Citations 335

Followers 0

Related Specialties

Rheumatology

General Medicine

Pulmonary Medicine

Top 10 Co-Authors

Shinji Maeda

Ryuzo Ueda

Shogo Banno

Yoshihito Hayami

Shiho Iwagaitsu

Shin-Ichiro Ohmura

Toru Yamabe

Shigeki Sato

Akio Niimi

Shin-Ya Tamechika

Published In

Mod Rheumatol

Nihon Kokyuki Gakkai Zasshi

Intern Med

Int J Rheum Dis

Case Rep Rheumatol

Affiliations

Soon will be listed here.

Recent Articles

11.

Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult-onset Still's disease receiving interleukin-6 inhibitor treatment

Naniwa T, Yamabe T, Ohmura S, Uehara K, Tamechika S, Maeda S, et al.

Int J Rheum Dis . 2022 Jun; 25(9):1003-1012. PMID: 35719030

Aim: Macrophage activation syndrome (MAS), a severe complication of systemic adult-onset Still's disease (AOSD), has been reported to occur during interleukin-6 (IL-6) inhibitor treatment. However, predictors for MAS development are...

12.

Impact of dysphagia and its severity on long-term survival and swallowing function outcomes in patients with idiopathic inflammatory myopathies other than inclusion body myositis

Ohmura S, Tamechika S, Miyamoto T, Kunieda K, Naniwa T

Int J Rheum Dis . 2022 Jun; 25(8):897-909. PMID: 35678075

Objective: To investigate the impact of dysphagia on long-term survival and swallowing function outcomes in patients with idiopathic inflammatory myopathy other than inclusion body myositis. Methods: We retrospectively evaluated consecutive...

13.

Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study

Azuma T, Misaki K, Kusaoi M, Suzuki Y, Higa S, Kumon Y, et al.

Mod Rheumatol . 2022 Apr; 33(2):271-278. PMID: 35389481

Objectives: We performed post-hoc analyses of the ORIGAMI study to investigate whether concomitant methotrexate (MTX) influences the clinical outcomes of abatacept in biologic-naïve patients with rheumatoid arthritis. Methods: Enrolled patients...

14.

Eosinophilic Granulomatosis with Polyangiitis Presenting with Central Retinal Artery Occlusion During Treatment with Anti-interleukin-5 Receptor Monoclonal Antibody

Nishiyama H, Tajiri T, Yamabe T, Yasukawa T, Takeda N, Fukumitsu K, et al.

Intern Med . 2021 Jun; 60(22):3631-3634. PMID: 34092731

Eosinophilic granulomatosis with polyangiitis (EGPA) is an anti-neutrophilic cytoplasm antibody (ANCA)-associated vasculitis characterized by asthma and eosinophilia. Although EGPA involves multiple organs, ocular involvement is infrequent and often carries a...

15.

Improvement of Chronic Rhinosinusitis and Reduction of the Myeloperoxidase-Antineutrophil Cytoplasmic Antibody Titer in a Patient with Eosinophilic Granulomatosis with Polyangiitis by Additional Mepolizumab

Tamechika S, Isogai S, Maeda S, Naniwa T, Niimi A

Case Rep Rheumatol . 2021 Apr; 2021:5561762. PMID: 33859858

A case of eosinophilic granulomatosis with polyangiitis (EGPA) in which chronic rhinosinusitis (CRS) was improved with a reduction in the myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) titer after the addition of mepolizumab...

16.

Macrophage activation syndrome in patients with adult-onset Still's disease under tocilizumab treatment: A single-center observational study

Yamabe T, Ohmura S, Uehara K, Naniwa T

Mod Rheumatol . 2021 Mar; 32(1):169-176. PMID: 33719871

Objectives: Macrophage activation syndrome (MAS) developed under tocilizumab treatment poses a diagnostic challenge. This study aims to demonstrate the frequency and the clinical features of MAS developed in patients with...

17.

Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, et al.

Arthritis Rheumatol . 2020 Oct; 73(4):677-686. PMID: 33118321

Objective: To establish predictive models for mortality in patients with polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD) using a combination of initial serum biomarker levels. Methods: The Multicenter Retrospective Cohort of Japanese...

18.

Successful use of short-term add-on tocilizumab for refractory adult-onset still's disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide

Ohmura S, Uehara K, Yamabe T, Tamechika S, Maeda S, Naniwa T

Mod Rheumatol Case Rep . 2020 Oct; 4(2):202-207. PMID: 33086994

Macrophage activation syndrome (MAS) is a form of secondary hemophagocytic lymphohistiocytosis (HLH) and is a life-threatening complication of adult-onset Still disease. MAS has been usually treated with high-dose glucocorticoid with...

19.

Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still's disease with a previous successful tocilizumab treatment

Naniwa T, Uehara K, Yamabe T, Ohmura S

Mod Rheumatol Case Rep . 2020 Sep; 5(2):360-364. PMID: 32883165

Macrophage activation syndrome (MAS) is a form of secondary hemophagocytic lymphohistiocytosis and is a rapidly progressive, life-threatening complication of adult-onset Still's disease (AOSD). An anti-IL-6 receptor monoclonal antibody, tocilizumab, has...

20.

Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies

Ohmura S, Yamabe T, Naniwa T

Mod Rheumatol Case Rep . 2020 Sep; 5(1):76-81. PMID: 32867615

Anti-melanoma differentiation-associated gene 5 (MDA-5) antibodies have widely known to be associated with amyopathic dermatomyositis with rapidly progressive interstitial lung disease (ILD). Although the triple combination therapy with high-dose glucocorticoids,...